Reply to: Correspondence on "High rates of 30-day mortality in patients with cirrhosis and COVID-19"

J Hepatol. 2020 Dec;73(6):1570-1571. doi: 10.1016/j.jhep.2020.08.001. Epub 2020 Aug 7.

CirCoV study group:
M Iavarone, R D'Ambrosio, A Rimondi, P Lampertico, A Soria, P Bonfanti, M Triolo, S Fagiuoli, N Pugliese, A Aghemo, P Del Poggio, G Perricone, L S Belli, S Massironi, M Lucà, P Invernizzi, A Spinetti, C Carriero, E Buscarini, M Pedaci, M Viganò, M G Rumi

¹ Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, CRC "A. M. and A. Migliavacca" Center for Liver Disease, Milan, Italy. Electronic address: [email protected].
² Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, CRC "A. M. and A. Migliavacca" Center for Liver Disease, Milan, Italy.
³ Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, CRC "A. M. and A. Migliavacca" Center for Liver Disease, Milan, Italy; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.

No abstract available

Keywords: HBV; HCV; Hepatitis; Hepatocellular carcinoma; Liver transplantation; SARS-CoV-2.

Publication types